Status:

TERMINATED

C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma

Lead Sponsor:

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Collaborating Sponsors:

Shanghai PerHum Therapeutics Co., Ltd.

Conditions:

Lymphoma, B-Cell

CAR-T

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

It is a single-arm, open-label clinical study to assess the safety and efficacy of the C752 CAR-T Cells for patients with CD19+ refractory/relapsed B cell non-Hodgkin lymphoma.

Eligibility Criteria

Inclusion

  • Written informed consent in accordance with federal, local, and institutional guidelines, Males and females ≥18 years of age at the time of consent
  • Documented diagnosis of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
  • Have progression by least one systemic treatment and no available standard of care treatment.
  • At least one measurable lesion by Lugano 2014
  • Expected survival ≥ 12 weeks
  • Have an ECOG performance status of 0 or 1
  • Adequate organ function
  • Screening test indicates histopathological CD19 + if the subject received CD19-targeted therapy
  • Women of childbearing age must have a negative pregnancy test, and agree to take effective contraception during the trial

Exclusion

  • Treatment with any prior HSCT, gene therapy product, cell therapy product ect.
  • Central nervous system involvement
  • HBV/HCV
  • HIV infection
  • Concurrent use of systemic steroids or immunosuppression
  • Uncontrolled active infection
  • Wash-out period of from the last anti-cancer treatment
  • Active second malignancy
  • Have not recovered from the effects of previous therapy
  • Have psychological or physical conditions that do not permit compliance with the protocol
  • Pregnant or nursing (lactating) women

Key Trial Info

Start Date :

December 24 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 24 2024

Estimated Enrollment :

2 Patients enrolled

Trial Details

Trial ID

NCT06210243

Start Date

December 24 2023

End Date

December 24 2024

Last Update

February 18 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

920th Hospital of Joint LogisticsSupport Force of People's Liberation

Kunming, Yunnan, China, 650000

C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma | DecenTrialz